Premium
Mapping of a human T‐lymphotropic virus type I gag protein epitope that cross‐reacts with anti‐ Plasmodium falciparum antibodies
Author(s) -
Porter Kevin R.,
Hayes Curtis G.,
Anthony Ronald L.,
Solihin Ating
Publication year - 1995
Publication title -
journal of medical virology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.782
H-Index - 121
eISSN - 1096-9071
pISSN - 0146-6615
DOI - 10.1002/jmv.1890450419
Subject(s) - epitope , plasmodium falciparum , virology , antibody , western blot , peptide sequence , biology , linear epitope , microbiology and biotechnology , malaria , immunology , biochemistry , gene
Studies in Palawan, Philippines, and Irian Jaya, Indonesia, showed that indeterminate human T‐lymphotropic virus type I (HTLV‐I) Western blot immunoreactivity is due to cross‐reacting anti‐ Plasmodium falciparum antibodies. To further define this immunoreactivity, mapping studies were conducted using the HTLV‐I p19 protein to identify the precise epitope that reacts with these antibodies. Anti‐ P. falciparum antibody‐positive sera from Palawan, Philippines, and Irian Jaya, Indonesia, were studied using overlapping synthetic peptides. Immunoreactivity was localized to residues 108–120 of p19. Further analysis of the sera with 5 biotinylated synthetic peptides showed that the cross‐reactive epitope consists of the sequence PDSDPQI (amino acid residues 110–116), which was shown to be homologous to a 7 amino acid sequence on the Exp‐1 protein of the P. falciparum blood stage parasite. This is the first study that identifies a specific HTLV‐I protein epitope that cross‐reacts with malaria antibodies. © 1995 Wiley‐Liss, Inc. This article is a US Government work and, as such, is in the public domain in the United States of America.